Breaking News

BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply

Amyris aims to develop up to three small molecule drugs over the next two years from the FDA drug shortage list.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amyris, an integrated synthetic biology and industrial biotechnology company, has been awarded an agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) for $12.3 million from the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to advance innovative pharmaceutical manufacturing in the U.S.   Using Amyris’ advanced technology in organism engineering, advanced precision fe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters